Navigation Links
The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies

rying levels dependent on factors such as receptor, cell type, and trafficking. The signal intensity increase observed with CypHer5E, compared to CypHer5, enables the monitoring of poorly expressed receptors. An example of this is shown in Figure 3. In addition to the δ-opioid cell line shown in Figure 2b (δ-opH), a lower expressing δ-opioid cell line was also generated (δ-opL). Expression levels of the two cell lines were determined by flow cytometry analysis. Signal to noise (S:N)* values were compared for four series of values (n = 4), each at the plateau for both CypHer5E and CypHer5. An average S:N value of 11.86 was obtained with CypHer5E, compared to 5.09 with CypHer5. The increased intensity and S:N values observed for CypHer5E with δ-opL indicate that the enhanced dye can compensate for the greater variation seen with lower expressors. Therefore users can still develop a robust assay. This is of particular benefit in assay development for screening applications. CypHer5E will provide the capability of monitoring the activation of lower expressing receptors than CypHer5. The data from Figure 3 also demonstrates very similar EC50 values for the same receptors at different expression levels.


Conclusion
CypHer5E is an enhanced pH-sensitive dye that can be applied to the functional analysis and screening of receptors that internalize into acidic endosomal vesicles upon ligand binding and activation. Using the IN Cell Analyzer 1000, a high-throughput lamp based sub-cellular imaging system, dose response data were obtained for a range of different GPCRs and a non-GPCR subtype. CypHer5E can be used to label antibodies that recognize an exofacial epitope on the target receptor, either endogenous to the protein or an inserted tag, the results are pharmacologically comparable to those obtained with CypHer5. The signal obtained with CypHer5E is significantly increased over that
'"/>

Source:


Page: All 1 2 3 4 5 6

Related biology technology :

1. Screening for potential beta 2-adrenergic receptor antagonists using CypHer5E and IN Cell Analyzer 1000
2. Analysis of in vitro micronucleus assays using the IN Cell Analyzer 3000 Micronuclei Formation Analysis Module
3. Screening for β2-adrenergic receptor agonists using the pH-sensitive dye,CypHer5, and the IN Cell Analyzer 3000
4. Identification of cells in S phase using the Cell Proliferation Fluorescence Kit and IN Cell Analyzer 1000
5. Rapid, High Throughput Mutation Discovery Using Fluorescent SSCP on the ABI PRISM 3100 and 3100Avant Genetic Analyzers
6. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
7. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
8. The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System
9. The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System
10. The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR
11. Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System
Post Your Comments:
(Date:7/30/2015)... ... July 31, 2015 , ... Ralco is honored to announce that it ... Fair to be held August 5-9 in Marshall. The Ralco Enrichment Center is an ... and how agriculture impacts their daily lives. This unique exhibit also features a birthing ...
(Date:7/30/2015)... 2015 According to a new ... Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract ... Trial), by End Users - Global Forecast to 2020", ... reach USD 2,107.99 million by 2020 from USD 1,034.93 ... Browse more than 75 ...
(Date:7/30/2015)... July 30, 2015 Ascendis Pharma A/S ... applies its innovative TransCon technology to address significant ... from a six-month Phase 2 study to evaluate ... Hormone in 53 treatment-naïve, pre-pubertal children with growth ... extremely pleased with the top-line results from our ...
(Date:7/29/2015)... 30, 2015 Sanofi, a ... the second quarter of 2015. CEO Olivier ... its performance in different businesses. Watch ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in the ... - Performance drivers - Diabetes ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:,ONC, ... has been granted,U.S. Patent 7,264,798 entitled "Sensitization ... Virus." The claims describe a method of,using ... drug,resistance to chemotherapeutic agents. "Recent research ...
... Hyatt New York on Monday, September 10th, ... a biopharmaceutical company developing patient-specific, active,immunotherapies for the ... Ph.D., President and Chief Executive Officer, will present ... 1:30 p.m. Eastern,time on Monday, September 10, 2007. ...
... in ... Hong Kong, China, SAN ... leading China biometrics company Miaxis,Biometrics Co., Ltd has been officially selected ... The news has been,announced at a gala dinner during the ,Red ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent 2Miaxis Biometrics Named as 'Red Herring 100 Asia' Award Winner for 2007 2Miaxis Biometrics Named as 'Red Herring 100 Asia' Award Winner for 2007 3
(Date:7/31/2015)... The 10 th International Conference on Genomics (ICG-10, ... in Shenzhen , China ... anniversary this year. Since its inauguration in 2006, ICG ... in the ,omics, fields, and is one of the most ... focuses on recent breakthroughs and advances in ,omics, research that ...
(Date:7/30/2015)... , July 30, 2015 Cellecta, ... for gene function analysis and biomarker discovery, announced ... (sgRNA) Knockout Library targeting all human protein coding ... permanently "knock out" a gene,s function. Cellecta,s new ... high throughput screening tool so that researchers can ...
(Date:7/27/2015)... JOSE, Calif. , July 27, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... ® touchscreen solution for its stylish smartwatch. ... for its proven reliability, low power and highly ... a wet finger. Huawei designers also required a ...
Breaking Biology News(10 mins):The 10th International Conference on Genomics (ICG-10) to Open in October 2CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... from “vile and cynical exploitation?by the alternative medicines industry, argues ... estimated that up to 80% of all patients with cancer ... help treat their cancer, writes Jonathan Waxman, Professor of Oncology ... the use of many of these approaches is obtuse ?one ...
... chemotherapy with short-term structural changes in cognitive areas ... Published in the January 1, 2007 issue of ... the American Cancer Society, the study reveals that ... regions of the brain associated with memory, analysis ...
... by other patients whose treatment has to be dropped to ... New guidance from the National Institute for health and Clinical ... it provides no extra funding and does not suggest what ... leaves medical staff with difficult decisions to make. , ...
Cached Biology News:Protect patients from exploitation by alternative medicines industry 2Chemotherapy temporarily affects the structures of the human brain 2Other patients bear the real cost of Herceptin 2
... Assay with FAM-Labeled Substrate (green fluorescence; ... measure serine protease activation • No ... FLISP Kits utilize cell-permeable, fluorescently labeled ... measure chymotrypsin-like activity in whole living ...
... Engine instrument is the cycler that ... thermal uniformity and swappable blocks ensure ... This rugged machine is more ... platform for new features and upgrades ...
... The Easy Cap tool provides ... seat domed double-locking caps in tubes ... has a wide end that firmly ... prevent accidental crushing when opening or ...
... Multiple Species Tissue Array (MSTA) slides were designed ... and tissues from multiple species. Tissue slices ... MSTA slide which can then be treated as ... or in situ hybridization. This ...
Biology Products: